RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All TGA (Australia) updates
TGA (Australia)
SAFETY ALERT
Update on Vyvanse (lisdexamfetamine dimesilate) investigation
Published: 9/25/2025Detected: 3/25/2026

Summary preview

Updates the status of TGA’s investigation into concerns regarding Vyvanse’s potential effectiveness, quality, and safety, concluding that no issues of regulatory concern were identified.

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
safety
quality
clinical
#Vyvanse
#lisdexamfetamine dimesilate
#TGA
#pharmacovigilance
#product safety

Official Source Document
Source Verified

Access the original document directly from TGA.

View Official Document

More from TGA (Australia)

  • TGA issues infringement notices to 3 health practitioners for alleged unlawful importation of therapeutic goods3/25/2026
  • Improving the regulation of sunscreens in Australia3/25/2026
  • Counterfeit weight loss products claiming to contain GLP-13/1/2026
  • Natures Valley Collagen Builder tablets2/15/2026
  • Vape enforcement crackdown with major seizure in Burwood NSW2/9/2026

Get TGA (Australia) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.